Stay updated on Dapirolizumab Pegol in Lupus: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Dapirolizumab Pegol in Lupus: Efficacy and Safety Clinical Trial page.

Latest updates to the Dapirolizumab Pegol in Lupus: Efficacy and Safety Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page's release version was updated from v3.6.6 to v3.7.0, indicating an underlying platform update for the Record History page. This change does not modify the recorded study history data.SummaryDifference0.1%

- Check23 days agoChange DetectedThe record history now shows the study status updated to Completed and the recruitment status set to No longer looking for participants, indicating enrollment has ended.SummaryDifference0.0%

- Check37 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6 on the page, signaling a new site version is in use. This is a metadata update and does not modify the study data or visible record content.SummaryDifference0.0%

- Check51 days agoChange DetectedThe revision history now shows a new version (v3.6.5) replacing the previous v3.6.4, indicating a site update. This is a metadata update and does not change the study details or user-facing content.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3 in the footer. This reflects a new software release/build reference for the ClinicalTrials.gov interface.SummaryDifference0.0%

- Check94 days agoChange DetectedThe history now indicates a new site revision: v3.6.3 replaces the previous v3.6.2. This reflects a routine site update rather than any change to the study information.SummaryDifference0.0%

Stay in the know with updates to Dapirolizumab Pegol in Lupus: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapirolizumab Pegol in Lupus: Efficacy and Safety Clinical Trial page.